Trends in the use of immunotherapy to treat soft tissue sarcoma

被引：1

作者：

Iwai, Yoshiko ^{[1
]}

Baldwin, Xavier L. ^{[1
]}

Feeney, Timothy ^{[2
]}

Agala, Chris B. ^{[1
]}

Yanagihara, Ted K. ^{[3
]}

Stein, Jacob N. ^{[4
]}

Kim, Hong Jin ^{[5
]}

Spanheimer, Philip M. ^{[5
]}

机构：

[1] Univ North Carolina Chapel Hill, Dept Surg, Chapel Hill, NC USA

[2] Univ North Carolina Chapel Hill, Gillings Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA

[3] Univ North Carolina Chapel Hill, Dept Radiat Oncol, Chapel Hill, NC USA

[4] Univ North Carolina Chapel Hill, Dept Med Oncol, Chapel Hill, NC USA

[5] Univ North Carolina Chapel Hill, Dept Surg, Div Surg Oncol, Chapel Hill, NC USA

来源：

AMERICAN JOURNAL OF SURGERY | 2024年 / 236卷

关键词：

Sarcoma; Soft tissue sarcoma; Soft tissue mass; Immunotherapy; Immune checkpoint inhibitor; SURVIVAL; INSIGHTS; CANCER; TUMORS;

D O I：

10.1016/j.amjsurg.2024.115794

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Background: The role of immune-oncology (IO) therapy in soft tissue sarcoma (STS) is underexplored. This study characterized IO use in STS. Methods: This is a retrospective analysis of patients with a soft tissue mass in the National Cancer Database, 2011-2021. Patients were categorized by IO receipt status. Groupwise testing and proportional trend tests were performed with Chi-squared tests. Multivariate logistic regression was performed to assess factors associated with IO receipt. Results: Of the 103,092 patients with STS, 1935 (1.9 %) received or were recommended IO therapy. IO use increased 10-fold (0.24 %-2.5 % from 2011 to 2021; p < 0.0001). Patients had higher odds of receiving IO when having higher grade tumors and metastatic disease, and when treated at an academic research center (all p < 0.001). Conclusions: IO use in STS is low but increasing and primarily used in the metastatic setting. Future studies should identify biomarkers of IO response and facilitators for treatment receipt.

引用

页数：8

共 50 条

[21] Soft Tissue Sarcoma Presenting With Metastatic Disease [J].

Ferguson, Peter C. ;

Deheshi, Benjamin M. ;

Chung, Peter ;

Catton, Charles N. ;

O'Sullivan, Brian ;

Gupta, Abha ;

Griffin, Anthony M. ;

Wunder, Jay S. .

CANCER, 2011, 117 (02) :372-379

[22] Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma [J].

Albertsmeier, Markus ;

Altendorf-Hofmann, Annelore ;

Lindner, Lars H. ;

Issels, Rolf D. ;

Kampmann, Eric ;

Duerr, Hans-Roland ;

Schubert-Fritschle, Gabriele ;

Angele, Martin K. ;

Kirchner, Thomas ;

Jungbluth, Achim A. ;

Knoesel, Thomas .

CANCERS, 2020, 12 (12) :1-13

[23] Correlations between the modification patterns mediated by pyroptosis-related genes, tumor microenvironment, and immunotherapy in soft tissue sarcoma [J].

Cai, Yang ;

Meng, Jinzhi ;

Qiu, Yue ;

Huang, Xing ;

Du, Huawei ;

Yao, Jun .

MEDICINE, 2024, 103 (20) :E38173

[24] Comprehensive profiling of immune-related genes in soft tissue sarcoma patients [J].

Hu, Chuan ;

Chen, Bo ;

Huang, Zhangheng ;

Liu, Chuan ;

Ye, Lin ;

Wang, Cailin ;

Tong, Yuexin ;

Yang, Jiaxin ;

Zhao, Chengliang .

JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)

[25] Soft tissue sarcoma incidences and clinical characteristics are significantly different in France and Taiwan [J].

Chen, Tom Wei-Wu ;

Chiang, Ruru Chun-Ju ;

Le Cesne, Alex ;

Hsieh, Yu-Chun ;

Italiano, Antoine ;

Yang, Ya-Wen ;

Penel, Nicolas ;

Lee, Wen-Chung ;

Bompas, Emmanuelle ;

Valentin, Thibaud ;

Anract, Philippe ;

Firmin, Nelly ;

Duffaud, Florence ;

Cheng, Ann-Lii ;

Ducimetiere, Francoise ;

Chan, K. Arnold ;

Blay, Jean-Yves .

CANCER, 2022, 128 (18) :3360-3369

[26] Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor [J].

Baldi, Giacomo G. ;

Gronchi, Alessandro ;

Tazzari, Marcella ;

Stacchiotti, Silvia .

EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (05) :491-503

[27] Analysis of Clinical Outcomes of Patients with Soft Tissue Sarcoma [J].

Garg, Lokesh ;

Pruthi, Manish ;

Batra, Ullas ;

Doval, D. C. ;

Pasricha, Sunil ;

Jaipuria, Jiten ;

Virk, Jagandeep Singh ;

Tiwari, Akshay .

INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2022, 13 (03) :518-524

[28] Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma [J].

Loi, Mauro ;

Duijm, Marloes ;

Baker, Sarah ;

Rossi, Linda ;

Grunhagen, Dirk ;

Verhoef, Cornelis ;

Nuyttens, Joost .

RADIOLOGIA MEDICA, 2018, 123 (11) :871-878

[29] Treatment Strategy for Elderly Patients with Soft Tissue Sarcoma [J].

Nakamura, Tomoki ;

Sudo, Akihiro .

CURRENT ONCOLOGY REPORTS, 2022, 24 (05) :563-571

[30] ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review [J].

Andritsch, Elisabeth ;

Beishon, Marc ;

Bielack, Stefan ;

Bonvalot, Sylvie ;

Casali, Paolo ;

Crul, Mirjam ;

Delgado-Bolton, Roberto ;

Donatih, Davide Maria ;

Douis, Hassan ;

Haas, Rick ;

Hogendoorn, Pancras ;

Kozhaeva, Olga ;

Lavender, Verna ;

Lovey, Jozsef ;

Negrouk, Anastassia ;

Pereira, Philippe ;

Roca, Pierre ;

de Lempdes, Godelieve Rochette ;

Saarto, Tiina ;

van Berck, Bert ;

Vassal, Gilles ;

Wartenberg, Markus ;

Yared, Wendy ;

Costa, Alberto ;

Naredi, Peter .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 110 :94-105

← 1 2 3 4 5 →